Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01706991
Other study ID # rebiscan-003
Secondary ID
Status Completed
Phase N/A
First received October 5, 2012
Last updated October 12, 2012
Start date January 2011
Est. completion date June 2011

Study information

Verified date October 2012
Source Rebiscan, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Observational

Clinical Trial Summary

The purpose of this project is to compare the performance of the Pediatric Vision Scanner (PVS) with the Gold Standard Examination to determine the effectiveness of the PVS at detecting amblyopia and strabismus. All tests and observations will be done at a single visit over the course of approximately 30 minutes.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date June 2011
Est. primary completion date June 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 6 Months to 6 Years
Eligibility Inclusion Criteria:

- Children aged 6 months to 6 years

- Signed Informed consent by parent or guardian

- Meet all inclusion criteria.

Exclusion Criteria:

- Children with a history of developmental delay or cognitive deficit

- Children unable to complete the GSE (including visual acuity testing)

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Device:
Pediatric Vision Scanner eye scan
Subject is scanned with a 2.5 second pediatric vision scanner device test.

Locations

Country Name City State
United States Doheny Eye Institute Los Angeles California

Sponsors (2)

Lead Sponsor Collaborator
Rebiscan, Inc. University of Southern California

Country where clinical trial is conducted

United States, 

References & Publications (1)

Loudon SE, Rook CA, Nassif DS, Piskun NV, Hunter DG. Rapid, high-accuracy detection of strabismus and amblyopia using the pediatric vision scanner. Invest Ophthalmol Vis Sci. 2011 Jul 7;52(8):5043-8. doi: 10.1167/iovs.11-7503. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Binocularity score Day 1 Yes
Secondary Presence of amblyopia risk factors Day 1 Yes
See also
  Status Clinical Trial Phase
Recruiting NCT04238065 - A Clinical Trial of Caterna Virtual Reality Facilitating Treatment in Children With Amblyopia N/A
Completed NCT04432181 - Comparison of Deviation Types Among Astigmatic Children With Or Without Amblyopia
Terminated NCT02767856 - Regimens of Intermittent Occlusion Therapy for Amblyopia in Children N/A
Completed NCT02458846 - Efficacy of Visual Screening in Ontario N/A
Completed NCT01190813 - Levodopa for the Treatment of Residual Amblyopia Phase 3
Completed NCT01109459 - Multimodal Physician Intervention to Detect Amblyopia N/A
Completed NCT04313257 - Monocular Action Video Game Treatment of Amblyopia N/A
Completed NCT04315649 - Effect of 3D Movie Viewing on Stereopsis in Strabismus and / or Anisometropic Amblyops N/A
Completed NCT05223153 - OCT-A and Amblyopia
Recruiting NCT05522972 - Establishing New Treatment Approaches for Amblyopia: Perceptual Learning and Video Games N/A
Completed NCT01430247 - Vision Screening for the Detection of Amblyopia N/A
Completed NCT02200211 - Study of Binocular Computer Activities for Treatment of Amblyopia N/A
Recruiting NCT06429280 - Clinical Data Registry of Amblyopia Patients on Luminopia Treatment
Withdrawn NCT04959422 - Assuring Ophthalmologic Follow up N/A
Active, not recruiting NCT05612568 - 5 Years of Eye Screening for ARF in Children Aged <3 Years in Flanders
Recruiting NCT03655912 - Binocular Visual Therapy and Video Games for Amblyopia Treatment. N/A
Recruiting NCT06150391 - Evaluation of Amblyopia Protocols Using a Dichoptic Gabor Videogame Program N/A
Completed NCT03754153 - Binocularly Balanced Viewing Study N/A
Terminated NCT02246556 - Dichoptic Virtual Reality Therapy for Amblyopia in Adults Phase 1
Withdrawn NCT02594358 - Caffeine in Amblyopia Study Phase 1/Phase 2